Inactive Instrument

Mylan N.V. Stock price Nasdaq

Equities

MYL

NL0011031208

Pharmaceuticals

Sales 2024 * 15.2B Sales 2025 * 14.92B Capitalization 14.05B
Net income 2024 * 1.88B Net income 2025 * 989M EV / Sales 2024 * 1.8 x
Net Debt 2024 * 13.28B Net Debt 2025 * 11.4B EV / Sales 2025 * 1.71 x
P/E ratio 2024 *
8.17 x
P/E ratio 2025 *
13.6 x
Employees -
Yield 2024 *
4.25%
Yield 2025 *
4.42%
Free-Float 97.89%
More Fundamentals * Assessed data
Dynamic Chart

Latest transcript on Mylan N.V.

Managers TitleAgeSince
Chief Executive Officer 61 22-12-28
President 63 20-11-15
Chief Tech/Sci/R&D Officer - -
Members of the board TitleAgeSince
Chairman 56 20-11-15
Director/Board Member 68 20-11-15
Director/Board Member 66 20-11-15
More insiders
Viatris Inc. (Viatris) is a global healthcare company. The Company's segments include Developed Markets, Greater China, JANZ, and Emerging Markets. Its Developed Markets segment comprises its operations primarily in North America and Europe. The Greater China segment includes its operations in mainland China, Taiwan and Hong Kong. The JANZ segment consists of its operations in Japan, Australia and New Zealand. The Emerging Markets segment encompasses its presence in more than 125 countries with developing markets and emerging economies, as well as the Company's ARV franchise. Its portfolio comprises over 1,400 approved molecules across a range of key therapeutic areas, including key brands and complex generics. It operates around 40 manufacturing sites worldwide, which produce oral solid doses, injectables, complex dosage forms and active pharmaceutical ingredients. Its products include Lyrica, Lipitor, Creon, Influvac, Wixela Inhub, EpiPen Auto Injector, Fraxiparine and Yupelri.
Related indices
More about the company
  1. Stock
  2. Equities
  3. Stock Viatris Inc.
  4. Stock Mylan N.V. - Nasdaq